Clinical Trials

Title

A Randomized, Double-Blind, Placebo-Controlled study to Assess the Effects of Bempedoic Acid (ETC-1002) on the occurrence of Major Cardiovascular Events in Patients with, or at High Risk for Cardiovascular Disease who are Statin-Intolerant

Description

The primary objective is to evaluate whether administration of bempedoic acid 180 mg/day versus placebo reduces the risk of MACE in patients with, or at high risk for, CVD who are statin intolerant. This will be assessed with a composite primary efficacy endpoint that includes time to first occurrence of CV death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for unstable angina, or coronary revascularization.